Argentine company Bagó has entered a joint venture with Dutch firm Synthon. The new enterprise, Synthon Bagó, is to specialise in multiple sclerosis.
Argentine company Bagó has entered a joint venture with Dutch firm Synthon.
The new enterprise, Synthon Bagó, is to specialise in multiple sclerosis.
The agreement, sealed in Amsterdam, Holland, specifies that the company will focus on biological and biotechnological products but Pharmabiz understands that it intends to compete with leading MS products such as Merck Serono’s Rebif and Biogen’s Avonex.
The team is already settled at Bago’s headquarters, where the company has its Mass Consumption division.
Carlos Pellegrini was appointed General Manager of the new company, and Sergio Guerrero was designated as Marketing Manager. Both come from Bagó.
Pharmabiz interviewed the company’s official spokesmen and they did not want to talk about the operation.
Last month the laboratory made a public campaign to promote its 80 years of life that highlights the fact that the company has 11 pharmaceutical and pharmachemical factories in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico, Pakistan and Uruguay. See campaign
In Argentina, the company has 3 manufacturing centers, one in La Plata, another specialized in antibiotics located in La Rioja, and one pharmachemical factory in City Bell, province of Buenos Aires.
Synthon, on the other hand, has a raw materials manufacturing center in the province of Santa Fe.
